FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the…
Read More...
Read More...
